ISCO International Stem Cell CORP

  1. Stocks
  2. Healthcare
  3. OTC: ISCO

Price (delayed)

$0.11

Market cap

$880,483

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$0.21

Enterprise value

$4.51M

Highlights
The company's EPS has surged by 62% YoY and by 45% QoQ
ISCO's net income has soared by 60% YoY and by 44% QoQ
The equity has contracted by 20% YoY but it has grown by 8% from the previous quarter
The quick ratio has declined by 41% year-on-year and by 12% since the previous quarter
The revenue has contracted by 29% YoY
Sector: Healthcare
Industry: Biotechnology
Peers: IBIO CYDY CMRX

Key stats

What are the main financial stats of ISCO
Market
Shares outstanding
8M
Market cap
$880,483
Enterprise value
$4.51M
Valuations
Price to earnings (P/E)
N/A
Price to book (P/B)
N/A
Price to sales (P/S)
0.13
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
0.7
Earnings
Revenue
$6.45M
EBIT
-$1.52M
EBITDA
-$992,000
Free cash flow
-$1.35M
Per share
EPS
-$0.21
Free cash flow per share
-$0.17
Book value per share
-$0.55
Revenue per share
$0.83
TBVPS
$0.56
Balance sheet
Total assets
$5.61M
Total liabilities
$5.62M
Debt
$4.38M
Equity
-$4.31M
Working capital
-$1.65M
Liquidity
Debt to equity
-1.02
Current ratio
0.63
Quick ratio
0.29
Net debt/EBITDA
-3.66
Margins
EBITDA margin
-15.4%
Gross margin
59.8%
Net margin
-25.6%
Operating margin
-38.8%
Efficiency
Return on assets
-29%
Return on equity
N/A
Return on invested capital
-34%
Return on capital employed
-128.9%
Return on sales
-23.6%
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

ISCO stock price

How has the International Stem Cell stock price performed over time
Intraday
22.22%
1 week
57.14%
1 month
17.65%
1 year
-16.67%
YTD
77.42%
QTD
80.33%

Financial performance

How have International Stem Cell's revenue and profit performed over time
Revenue
$6.45M
Gross profit
$3.86M
Operating income
-$2.5M
Net income
-$1.65M
Gross margin
59.8%
Net margin
-25.6%
ISCO's net income has soared by 60% YoY and by 44% QoQ
The operating income has grown by 45% YoY and by 15% from the previous quarter
International Stem Cell's net margin has increased by 44% from the previous quarter and by 44% YoY
The revenue has contracted by 29% YoY

Growth

What is International Stem Cell's growth rate over time

Valuation

What is International Stem Cell stock price valuation
P/E
N/A
P/B
N/A
P/S
0.13
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
0.7
The company's EPS has surged by 62% YoY and by 45% QoQ
The equity has contracted by 20% YoY but it has grown by 8% from the previous quarter
ISCO's P/S is 81% below its last 4 quarters average of 0.7
The revenue has contracted by 29% YoY

Efficiency

How efficient is International Stem Cell business performance
ISCO's return on invested capital has surged by 63% year-on-year and by 44% since the previous quarter
The ROA has soared by 50% YoY and by 41% from the previous quarter
The company's return on sales rose by 47% YoY and by 46% QoQ

Dividends

What is ISCO's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for ISCO.

Financial health

How did International Stem Cell financials performed over time
The quick ratio has declined by 41% year-on-year and by 12% since the previous quarter
International Stem Cell's current ratio has decreased by 24% YoY and by 3.1% QoQ
The equity has contracted by 20% YoY but it has grown by 8% from the previous quarter
International Stem Cell's debt to equity has increased by 17% YoY and by 6% from the previous quarter

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.